Background: Gender-affirming hormone therapy (GAHT), which transgender individuals undergo, may influence several aspects of musculoskeletal health through changes in sex hormone profiles. With regard to bone tissue, the available evidence overall indicates substantial preservation of bone mineral density (BMD) during GAHT, although data on longer-term effects are still limited. Changes in body composition are more evident: in individuals assigned female at birth (AFAB), testosterone therapy is generally associated with an increase in lean mass and a reduction in fat mass, whereas in individuals assigned male at birth (AMAB), estrogen therapy results in changes in the opposite direction. Evidence regarding the effects of GAHT on muscle strength remains more limited and not entirely consistent. Aim of the study: To evaluate the effects of GAHT on bone mineral density, body composition, and muscle strength in AFAB and AMAB individuals after 24 months of treatment. Materials and methods: This longitudinal study included 42 transgender individuals naïve to GAHT (23 AFAB and 19 AMAB) attending the Regional Reference Center for Gender Incongruence (CRRIG) at the University Hospital of Padua. Participants were evaluated before treatment initiation and after 24 months through the collection of clinical, anthropometric, and biochemical parameters. Bone mineral density and body composition were assessed by dual-energy X-ray absorptiometry (DXA), and muscle strength by handgrip test. Results: After 24 months of GAHT, BMD remained stable in both groups at all skeletal sites considered. In AFAB individuals, a slight reduction in Z-score was observed at the lumbar spine (-0.77) and total hip (-0.40), together with an increase in femoral neck Z-score (+1.30). In AMAB individuals, a significant increase in femoral neck Z-score (+0.79) was also observed. Body composition showed changes in opposite directions in the two groups. In AFAB individuals, lean mass increased from 44.83 to 49.75 kg, in parallel with an increase in fat-free mass index (FFMI) from 16.35 to 18.40 kg/m². In AMAB individuals, fat mass increased from 11.75 to 15.82 kg and fat mass index (FMI) from 3.47 to 5.04 kg/m², accompanied by a reduction in FFMI from 17.4 to 16.7 kg/m². Muscle strength showed no statistically significant changes after 24 months of treatment in either group. Conclusions: The results highlight that the effects of GAHT at 24 months differ across the different components considered, with more evident changes in body composition alongside substantial stability in bone mineral density and muscle strength. Overall, these findings contribute to expanding the available evidence on the medium-term musculoskeletal effects of GAHT. Longitudinal studies conducted in larger populations and with longer follow-up will be needed to define the clinical relevance and evolution over time of the observed changes.
Presupposti dello studio: la terapia ormonale di affermazione di genere (GAHT) a cui si sottopongono le persone transgender, attraverso la modificazione del profilo degli ormoni sessuali, può influenzare diversi aspetti della salute muscoloscheletrica. Per quanto riguarda il tessuto osseo, le evidenze disponibili indicano nel complesso una sostanziale conservazione della densità minerale ossea (BMD, Bone Mineral Density) durante la GAHT, sebbene i dati relativi agli effetti a più lungo termine siano ancora limitati. Più evidenti sono le modificazioni della composizione corporea: negli individui assegnati femmina alla nascita (AFAB), la terapia con testosterone si associa generalmente a un incremento della massa magra e a una riduzione della massa grassa, mentre negli individui assegnati maschio alla nascita (AMAB) la terapia estrogenica determina modificazioni di segno opposto. Le evidenze relative agli effetti della GAHT sulla forza muscolare rimangono invece più limitate e non del tutto concordi. Scopo dello studio: valutare gli effetti della GAHT sulla densità minerale ossea, sulla composizione corporea e sulla forza muscolare in individui AFAB e AMAB dopo 24 mesi di trattamento. Materiali e metodi: lo studio longitudinale ha coinvolto 42 persone transgender naïve alla GAHT (23 AFAB e 19 AMAB), afferenti al Centro di Riferimento Regionale per l’Incongruenza di Genere dell’Azienda Ospedale-Università di Padova. I partecipanti sono stati valutati prima dell’inizio della terapia e dopo 24 mesi, attraverso la raccolta di parametri clinici, antropometrici e biochimici. La densità minerale ossea e la composizione corporea sono state valutate mediante assorbimetria a raggi X a doppia energia (DXA) e la forza muscolare mediante handgrip test. Risultati: dopo 24 mesi di GAHT, la BMD è rimasta stabile in entrambi i gruppi in tutti i siti scheletrici considerati. Negli individui AFAB si è osservata una lieve riduzione dello Z-score a livello lombare (-0,77) e dell’anca totale (-0,40), associata a un incremento dello Z-score del collo femorale (+1,30). Un incremento significativo dello Z-score del collo femorale (+0,79) è stato riscontrato anche negli individui AMAB. La composizione corporea ha mostrato modificazioni di segno opposto nei due gruppi. Nelle persone AFAB la massa magra è aumentata da 44,83 a 49,75 kg, parallelamente all’incremento dell’indice di massa magra (FFMI, Fat-Free Mass Index) da 16,35 a 18,40 kg/m². Negli AMAB si è osservato un aumento della massa grassa da 11,75 a 15,82 kg e dell’indice di massa grassa (FMI, Fat Mass Index) da 3,47 a 5,04 kg/m², accompagnato da una riduzione del FFMI da 17,4 a 16,7 kg/m². La forza muscolare non ha mostrato variazioni statisticamente significative dopo 24 mesi di trattamento in entrambi i gruppi. Conclusioni: i risultati evidenziano come gli effetti della GAHT a 24 mesi interessino in maniera differente i diversi compartimenti considerati, con modificazioni più evidenti della composizione corporea a fronte di una sostanziale stabilità della densità minerale ossea e della forza muscolare. Nel complesso, i dati ottenuti contribuiscono ad ampliare le evidenze disponibili sugli effetti muscoloscheletrici della GAHT nel medio termine. Studi longitudinali condotti su popolazioni più ampie e con follow-up prolungati saranno necessari per definire la rilevanza clinica e l’evoluzione nel tempo delle modificazioni osservate.
Impatto a medio termine della terapia ormonale su densità minerale ossea e composizione corporea nella popolazione transgender
PROCACCI, STEFANIA
2025/2026
Abstract
Background: Gender-affirming hormone therapy (GAHT), which transgender individuals undergo, may influence several aspects of musculoskeletal health through changes in sex hormone profiles. With regard to bone tissue, the available evidence overall indicates substantial preservation of bone mineral density (BMD) during GAHT, although data on longer-term effects are still limited. Changes in body composition are more evident: in individuals assigned female at birth (AFAB), testosterone therapy is generally associated with an increase in lean mass and a reduction in fat mass, whereas in individuals assigned male at birth (AMAB), estrogen therapy results in changes in the opposite direction. Evidence regarding the effects of GAHT on muscle strength remains more limited and not entirely consistent. Aim of the study: To evaluate the effects of GAHT on bone mineral density, body composition, and muscle strength in AFAB and AMAB individuals after 24 months of treatment. Materials and methods: This longitudinal study included 42 transgender individuals naïve to GAHT (23 AFAB and 19 AMAB) attending the Regional Reference Center for Gender Incongruence (CRRIG) at the University Hospital of Padua. Participants were evaluated before treatment initiation and after 24 months through the collection of clinical, anthropometric, and biochemical parameters. Bone mineral density and body composition were assessed by dual-energy X-ray absorptiometry (DXA), and muscle strength by handgrip test. Results: After 24 months of GAHT, BMD remained stable in both groups at all skeletal sites considered. In AFAB individuals, a slight reduction in Z-score was observed at the lumbar spine (-0.77) and total hip (-0.40), together with an increase in femoral neck Z-score (+1.30). In AMAB individuals, a significant increase in femoral neck Z-score (+0.79) was also observed. Body composition showed changes in opposite directions in the two groups. In AFAB individuals, lean mass increased from 44.83 to 49.75 kg, in parallel with an increase in fat-free mass index (FFMI) from 16.35 to 18.40 kg/m². In AMAB individuals, fat mass increased from 11.75 to 15.82 kg and fat mass index (FMI) from 3.47 to 5.04 kg/m², accompanied by a reduction in FFMI from 17.4 to 16.7 kg/m². Muscle strength showed no statistically significant changes after 24 months of treatment in either group. Conclusions: The results highlight that the effects of GAHT at 24 months differ across the different components considered, with more evident changes in body composition alongside substantial stability in bone mineral density and muscle strength. Overall, these findings contribute to expanding the available evidence on the medium-term musculoskeletal effects of GAHT. Longitudinal studies conducted in larger populations and with longer follow-up will be needed to define the clinical relevance and evolution over time of the observed changes.| File | Dimensione | Formato | |
|---|---|---|---|
|
PROCACCI_STEFANIA.pdf
accesso aperto
Dimensione
1.16 MB
Formato
Adobe PDF
|
1.16 MB | Adobe PDF | Visualizza/Apri |
The text of this website © Università degli studi di Padova. Full Text are published under a non-exclusive license. Metadata are under a CC0 License
https://hdl.handle.net/20.500.12608/116693